Details for Patent: 5,580,880

Summary for Patent: 5,580,880

Title:	Method for the treatment of xerostomia
Abstract:	A method for the treatment of xerostomia not caused by Sjogren's syndrome comprising administering to an affected individual an effective amount of a derivative of spirooxathiolane-quinuclidine.
Inventor(s):	Harumi Handa, Yasuyoshi Takeshita
Assignee:	Daiichi Pharmaceutical Co Ltd
Application Number:	US08/466,373
Patent Claim Types: see list of patent claims	Use;

United States Patent 5,580,880: Scope of Claims, Formula Coverage, and US Patent Landscape for Spirooxathiolane-Quinuclidine Xerostomia

Executive summary: US Patent 5,580,880 claims US-method-of-use coverage for treating xerostomia not caused by Sjogren’s syndrome using a spirooxathiolane-quinuclidine derivative (or an acid-addition salt) defined by a structural formula (I), with dependent claim narrowing to 2-methylspiro(1,3-oxathiolane-5,3’)quinuclidine hydrochloride (formula II) and to the cis isomer. The claim set is structurally anchored (formula I/II) and clinically anchored (exclusion of Sjogren’s), creating a focused but potentially workable infringement hook for “non-Sjogren xerostomia” formulations and isomer-specific products. The principal landscape risk for exclusivity is that generic or alternative developers can design around either (a) the claimed chemical class (formula I substituent scope), (b) the salt/isomer limits in dependent claims, or (c) the indication through labels and studies framed around Sjogren’s or other etiologies.

---

What does US Patent 5,580,880 claim for xerostomia treatment in the US?

Answer: It claims a method of treatment for non-Sjogren xerostomia by administering an effective amount of a spirooxathiolane-quinuclidine derivative (formula I) or an acid-addition salt. Dependent claims limit the chemical identity to 2-methylspiro(1,3-oxathiolane-5,3’)quinuclidine hydrochloride (formula II) and further limit stereochemistry to the cis isomer.

Claim 1 (independent): structural formula I + non-Sjogren xerostomia

Claim scope core elements

1. Indication: “xerostomia not caused by Sjogren’s syndrome.”
2. Administration: “administering … an effective amount of a therapeutic agent.”
3. Therapeutic agent definition:
   • “comprising a derivative of spirooxathiolane-quinuclidine or an acid addition salt”
   • represented by formula (I) where:
     • R1 and R2 may be the same or different
     • each is selected from: hydrogen, alkyl, cyclopentyl, cyclohexyl, aryl, diaryl methylol, or alkyl substituted by one or more aryl groups

Practical reading: Claim 1 does not require a specific compound name other than the structural class. It relies on formula I to cover a “family” of derivatives determined by substituent choices for R1 and R2. It also excludes Sjogren’s, which functions as an indication limitation that can matter for label design and for infringement theories based on medical practice.

Claim 2 (dependent): formula II identity lock to hydrochloride

Claim 2 specifies that the therapeutic agent comprises 2-methylspiro(1,3-oxathiolane-5,3’)quinuclidine hydrochloride represented by formula (II).

Practical reading: This collapses formula I family coverage into one identified member plus salt form. In litigation, claim 2 typically has stronger identification because it maps to a single chemical entity even if formula I could otherwise read on multiple derivatives.

Claim 3 (dependent): cis isomer limitation

Claim 3 narrows claim 2 by requiring the therapeutic agent to comprise the cis-isomer.

Practical reading: Claim 3 is stereochemistry-constrained. A product using the trans isomer, a racemate with different cis/trans proportion, or a different stereochemical composition could create design-around leverage depending on how claim construction handles “comprises,” percentage thresholds, and isomer purity.

---

How broad is the formula (I) coverage for spirooxathiolane-quinuclidine derivatives under claim 1?

Answer: Claim 1 covers spirooxathiolane-quinuclidine derivatives defined by formula I with substituent flexibility at the R1 and R2 positions: the claim enumerates several broad groups and also includes aryl-substituted alkyl and “diaryl methylol” options. This is broader than a single-compound patent but narrower than an open-ended genus without structural anchors.

R1/R2 enumerated substitution options

From the claim text, R1 and R2 can each be:

• Hydrogen
• Alkyl
• Cyclopentyl
• Cyclohexyl
• Aryl
• diaryl methylol
• alkyl which may be substituted by one or more aryl groups

Breadth implications for infringement and design-around

• Broad buckets (alkyl, aryl, cycloalkyl) can cover many drug-like substituents.
• Aralkyl (alkyl substituted by aryl groups) expands chemical design space.
• “Diaryl methylol” is narrower as a functional category but still can capture multiple aryl substitution patterns.

Design-around leverage for a competitor:

• If their candidate does not fit formula I substituent categories, claim 1 may be avoided on chemical grounds.
• If their compound fits formula I but the product is only prescribed/marketed for Sjogren’s or other etiologies, claim 1 may be avoided on indication grounds (in US method-of-use enforcement, label and actual practice often matter).

---

What does “acid addition salt” mean for the infringement scope in US 5,580,880?

Answer: Claim 1 includes acid addition salts of the derivative. That expands practical coverage beyond free base forms to salt forms that are pharmaceutically acceptable and that preserve the core structure.

Likely salt coverage categories

Because the claim text says “an acid addition salt thereof,” the scope can include hydrochloride, hydrobromide, sulfate, maleate, citrate, etc., as long as the salt is of the claimed derivative (formula I) and is an acid-addition salt rather than a different salt type (for example, quaternary ammonium salt is typically not an acid addition salt, but for quinuclidine systems, hydrochloride is usually treated as an acid-addition salt).

Claim 2’s hydrochloride anchor

Claim 2 specifically requires hydrochloride of the 2-methyl derivative. Even if hydrochloride is already within the “acid addition salt” generic category, claim 2 adds a stronger identity and salt constraint.

---

Which xerostomia indication limitation matters most for US infringement: “not caused by Sjogren’s syndrome”?

Answer: The indication exclusion is a material limitation in claim 1. It can affect enforceability by steering what medical practice is relevant for “administering … to an affected individual” under the claim.

How the indication limitation can shape enforcement theories

• If a product is labeled and used for Sjogren’s-related xerostomia only, a plaintiff’s method-of-use infringement theory for “not caused by Sjogren’s” becomes harder.
• If a product is broadly labeled for xerostomia without restricting to Sjogren’s and is used in non-Sjogren patients, the limitation may be satisfied depending on the patient subset treated.
• In parallel, even if the chemical is within formula I, the method claim requires the patient condition match.

Practical litigation posture for a chemical-class challenger

To test claim 1:

• Map the candidate compound to formula I substituent categories (R1/R2).
• Map the candidate’s marketed indication and typical prescribing patterns to the “not caused by Sjogren’s syndrome” condition.
• Evaluate whether “affected individual” evidence aligns with the exclusion.

---

What formulations are protected by US 5,580,880 (is it limited to a specific dosage form)?

Answer: The claims are method-of-treatment claims based on administering a therapeutic agent defined by chemical structure and salt/isomer. They do not expressly limit dosage form, route, or excipient composition in the provided claim text.

What is and is not claimed (based on the claim text provided)

• Not claimed: a specific formulation vehicle (tablet, solution, gel, patch), route (oral vs topical), or dose schedule.
• Claimed: administration of an effective amount of a defined spirooxathiolane-quinuclidine derivative (formula I / formula II / cis isomer).

Implication: A wide range of pharmaceutical formulations could fall within infringement if they deliver the claimed active in the claimed chemical form and are used in the claimed non-Sjogren xerostomia population.

---

What does dependent claim 2 add beyond claim 1, and how does it narrow potential infringement?

Answer: Claim 2 narrows the chemical identity to 2-methylspiro(1,3-oxathiolane-5,3’)quinuclidine hydrochloride.

Narrowing effects

• It removes ambiguity among other formula I derivatives.
• It pins enforcement to the specific active ingredient identity (and salt form).

Design-around options against claim 2

• Use a different R1/R2 combination producing a different derivative within or outside formula I, or
• Use the same derivative but as a non-hydrochloride salt (if a different salt avoids “hydrochloride” under claim 2, while still potentially falling under claim 1 depending on whether the candidate is still within formula I and is an acid-addition salt).

---

How does dependent claim 3’s “cis-isomer” requirement impact product design and stereochemical infringement?

Answer: Claim 3 requires the therapeutic agent to comprise the cis isomer. This creates an exploitable stereochemical boundary.

Infringement-relevant considerations

• If a competitor’s drug product uses the trans isomer exclusively, it can avoid claim 3.
• If a product is a mixture, “comprises the cis-isomer” could still read if cis is present in an amount meeting claim construction thresholds.
• Isomer purity specifications in the candidate product matter for mapping to “comprises.”

Design-around strategies

• Commercialize a stereochemical composition that does not include cis isomer as required by claim 3.
• Use the same base but different stereochemical outcome, while considering whether claim 1 or claim 2 still read depending on how “cis/trans” is treated under formula I structural definition.

---

What patent estate and related US IP typically surround a spirooxathiolane-quinuclidine xerostomia program?

Answer: Based on the claim structure, US 5,580,880 is positioned as a method-of-use protection for a defined chemical class. In typical medicinal-chemistry programs, the “family” around such a method claim often includes:

• composition-of-matter claims covering the active derivative(s) in free base and/or salts,
• stereochemistry-specific claims (including cis),
• process/manufacturing patents,
• formulation and dosing regimen patents,
• and possibly additional medical-use patents for xerostomia etiologies.

Important: Without a full bibliographic and cited-patent record for US 5,580,880 (family members, continuations, and earlier composition/process filings), the broader estate can’t be enumerated accurately here.

---

When does US Patent 5,580,880 expire, and does it have pediatric or term-adjustment extensions?

Answer: The expiration, any PTA/PTE, and any pediatric extension cannot be determined from the claim text alone and require the patent’s front-page data (filing date, issue date, priority chain, PTA/PTE entries).

---

What is the Orange Book status of US 5,580,880 and how does it affect generic entry risk?

Answer: Orange Book linkage status cannot be established from the claim text provided. Orange Book listings depend on whether the method-of-use is submitted for a specific FDA-approved NDA/ANDA and on the identity of the active ingredient(s) and dosage forms.

---

How strong is the claim scope for infringement in US litigation versus typical generic design-arounds?

Answer: Strength is highest when:

• the competitor uses a compound that fits formula I substituent scope,
• provides the relevant acid-addition salt form (at minimum to capture claim 1),
• uses cis isomer if relying on claim 3, and
• treats non-Sjogren xerostomia patients in a way aligned with the claim’s indication limitation.

Key infringement “hinges” (most litigated maps)

1. Chemical mapping: Does the candidate agent fall within formula I / formula II?
2. Salt mapping: Is the administered agent an acid-addition salt of the claimed derivative? For claim 2, is it specifically hydrochloride?
3. Isomer mapping: Is cis present and is cis required by claim 3?
4. Indication mapping: Is the patient population “not caused by Sjogren’s syndrome”?

Design-around priorities for challengers

• Change chemical substitution pattern outside R1/R2 enumerated options.
• Avoid the hydrochloride form for claim 2 (while checking claim 1 coverage).
• Avoid cis composition to reduce claim 3 exposure.
• Narrow therapeutic use toward Sjogren’s-related indications where possible.

---

Key Takeaways

• US 5,580,880 is a method-of-treatment patent for non-Sjogren xerostomia using spirooxathiolane-quinuclidine derivatives defined by formula (I).
• Claim 1 is a chemical-genus method claim with R1/R2 substituent flexibility and a strong indication exclusion for Sjogren’s.
• Claim 2 narrows to 2-methylspiro(1,3-oxathiolane-5,3’)quinuclidine hydrochloride (formula II).
• Claim 3 narrows further to the cis isomer, enabling stereochemical design-around.
• In US enforcement, the largest practical barriers for a generic or alternate entrant are typically formula mapping, salt/isomer mapping, and indication alignment for the “not caused by Sjogren’s syndrome” limitation.

---

FAQs

1. Can a product that treats xerostomia in Sjogren’s patients avoid infringement of a “not caused by Sjogren’s” method claim?
2. Does administering a free base versus an acid-addition salt affect infringement under claim 1 of US 5,580,880?
3. If a competitor uses a mixture of cis and trans isomers, does “comprises the cis-isomer” create continued claim 3 exposure?
4. What happens to claim 2 if the active is the same molecule but a non-hydrochloride acid-addition salt?
5. How do label indications and real-world prescribing patterns interact with method-of-use patents in non-Sjogren xerostomia cases?

---

References (APA)

1. US Patent 5,580,880, “Method for the treatment of xerostomia not caused by Sjogren’s syndrome,” claims as provided by user.

Drugs Protected by US Patent 5,580,880

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 5,580,880

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	6-168982	Jun 27, 1994

International Family Members for US Patent 5,580,880

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	205085
Australia	2324595
Australia	707236